The FDA approved Brilinta (ticagrelor) for reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndrome when taken with aspirin.
Laura M. Challen, PharmD, BCPS, MBA
Advertisement
Articles by Laura M. Challen, PharmD, BCPS, MBA
Advertisement
Latest Updated Articles
- AstraZeneca's Brilinta
Published: November 9th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Estradiol-Containing MHT May Impact Alzheimer Disease-Related Biomarkers in Postmenopausal Women
2
CHEST 2025: Improving Access to Chronic Cough Treatment Through a Digital Therapeutic Solution
3
MHT Use Can Affect Cognitive Health Depending on Administration Method
4
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
5
